TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from QuantumPharm, Inc. ( (HK:2228) ).
XtalPi Holdings Limited has announced the successful development of two new molecules, Remeanagen™ and AquaKine™, for hair growth and hair loss prevention using its AI molecular discovery platform. These molecules, combined in the product Groland, have shown superior performance in human trials and received key international certifications, marking XtalPi’s entry into the consumer healthcare sector. This development underscores the company’s commitment to leveraging AI for creating both life-saving drugs and consumer products that enhance daily life.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited, founded in 2015 by MIT physicists, is an innovative R&D platform that integrates quantum physics, artificial intelligence, and robotics. The company provides digital and intelligent R&D solutions across various industries, including pharmaceuticals, materials science, agricultural technology, energy, new chemicals, and cosmetics. XtalPi has collaborated with major companies like Pfizer and Lilly to develop groundbreaking medications and experimental molecules.
Average Trading Volume: 176,563,351
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$48.26B
Find detailed analytics on 2228 stock on TipRanks’ Stock Analysis page.